AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20862944 — intervention group
Group type: COMPARATOR
Intervention: Simple general anesthesia (Group B)
Number of subjects: 30
Study 18678300 — intervention group
Group type: EXPERIMENTAL
Intervention: P-OM3 + simvastatin
Number of subjects: 39
Study 18678300 — intervention group
Group type: COMPARATOR
Intervention: Placebo + simvastatin
Number of subjects: 39
Study 15950852 — intervention group
Group type: COMPARATOR
Intervention: Eyelid group (n = 30) with TOF stimulation
Number of subjects: 60
Study 15950852 — intervention group
Group type: COMPARATOR
Intervention: Eyelid group (n = 30) with DBS(3,3) stimulation
Number of subjects: 60
Study 15950852 — intervention group
Group type: COMPARATOR
Intervention: Eyelid group (n = 30) with DBS(3,2) stimulation
Number of subjects: 60
Study 12915664 — intervention group
Group type: EXPERIMENTAL
Intervention: 280-kCal preload
Number of subjects: 24
Study 12915664 — intervention group
Group type: COMPARATOR
Intervention: No preload
Number of subjects: 24
Study 16329539 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane filter
Number of subjects: 51
Study 16329539 — intervention group
Group type: COMPARATOR
Intervention: Non-woven polyester filter
Number of subjects: 51
Study 8889400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine dependence
Number of subjects: 50
Study 8889400 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol dependence
Number of subjects: 50
Study 8889400 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 50
Study 8889400 — intervention group
Group type: COMPARATOR
Intervention: Nicotine dependence
Number of subjects: 50
Study 2058190 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian method
Number of subjects: 34
Study 2058190 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiou method
Number of subjects: 34
Study 2058190 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric dosing algorithm
Number of subjects: 34
Study 6683463 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone, 100 mg orally every 8 hours for 1 month
Number of subjects: 13
Study 6683463 — intervention group
Group type: COMPARATOR
Intervention: Conventional CHF medications alone
Number of subjects: 13
Study 6683463 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 13
Study 30681720 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological management of delirium (PMD) bundle
Number of subjects: 351
Study 30681720 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 351
Study 28752695 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% diquafosol ophthalmic solution
Number of subjects: 30
Study 28752695 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30
Study 26927209 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised 3-month course of Occupational Therapy (OT) delivered by qualified therapists.
Number of subjects: 1042
Study 26927209 — intervention group
Group type: COMPARATOR
Intervention: Usual care for residents (Control).
Number of subjects: 1042
Study 26927209 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Therapy intervention for residents with stroke living in UK Care Homes.
Number of subjects: 1042
Study 24465030 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTP1 rs1138272 minor allele carriers
Number of subjects: 5115
Study 24465030 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTP1 rs1695 minor allele carriers
Number of subjects: 5115
Study 24465030 — intervention group
Group type: COMPARATOR
Intervention: Homozygous major allele carriers (for GSTP1 rs1138272)
Number of subjects: 5115
Study 24465030 — intervention group
Group type: COMPARATOR
Intervention: Homozygous major allele carriers (for GSTP1 rs1695)
Number of subjects: 5115
Study 24465030 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF genotype
Number of subjects: 5115
Study 21423036 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone Ahmed glaucoma valve implant with intravitreal triamcinolone acetonide
Number of subjects: 49
Study 21423036 — intervention group
Group type: COMPARATOR
Intervention: Silicone Ahmed glaucoma valve
Number of subjects: 49
Study 19903345 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention consisting of three visits to a Personal Vitality Coach (PVC) and a Vitality Exercise Programme (VEP) over 6 months, including weekly guided yoga and aerobic workout sessions, and encouragement for vigorous physical activity.
Number of subjects: 36
Study 19903345 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 36
Study 17396398 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic beverage (0.04 blood alcohol content)
Number of subjects: 42
Study 17396398 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 42
Study 16243088 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 422
Study 16243088 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B followed by fluconazole
Number of subjects: 422
Study 12045644 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation targeting SBP of 70 mm Hg (low)
Number of subjects: 110
Study 12045644 — intervention group
Group type: COMPARATOR
Intervention: Fluid resuscitation targeting SBP > 100 mm Hg (conventional)
Number of subjects: 110
Study 9459231 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane 2%-6%
Number of subjects: 120
Study 9459231 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 0.6%-1.75%
Number of subjects: 120
Study 9459231 — intervention group
Group type: COMPARATOR
Intervention: Propofol 50-150 microg x kg(‐1) x min(‐1)
Number of subjects: 120
Study 8527264 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (4 mg)
Number of subjects: 35
Study 8527264 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (20 mg)
Number of subjects: 35
Study 8527264 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (1 mg)
Number of subjects: 35
Study 2508009 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro food specific IgE tests
Number of subjects: 37
Study 2508009 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG radioallergosorbent tests
Number of subjects: 37
Study 2508009 — intervention group
Group type: EXPERIMENTAL
Intervention: Food enzyme-linked immune complex assays
Number of subjects: 37
Study 2508009 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo Multi-Test prick tests
Number of subjects: 37
Study 2508009 — intervention group
Group type: COMPARATOR
Intervention: Oral challenge food test (OCFT)
Number of subjects: 37
Study 69191 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen as an adjuvant in radiotherapy
Number of subjects: 0
Study 69191 — intervention group
Group type: COMPARATOR
Intervention: Air (control group)
Number of subjects: 0
Study 69191 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (3500 rads in 10 fractions over 3 weeks)
Number of subjects: 0
Study 31094434 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based intervention (6-session, telephone-based intervention)
Number of subjects: 21
Study 31094434 — intervention group
Group type: COMPARATOR
Intervention: Education control
Number of subjects: 21
Study 27647376 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic ultrasound (US) measuring maximal diaphragmatic excursion (MDE)
Number of subjects: 67
Study 27647376 — intervention group
Group type: COMPARATOR
Intervention: Medical Research Council (MRC) score
Number of subjects: 67
Study 25083980 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxalated hemoglobin polyoxyethylene (20 mg Hb/kg/hr)
Number of subjects: 377
Study 25083980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377
Study 25083980 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxalated hemoglobin polyoxyethylene
Number of subjects: 377
Study 23412099 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 30 mg/m² on days 1 and 8, every 3 weeks and cetuximab 400 mg/m² on day 1, then 250 mg/m² weekly
Number of subjects: 38
Study 21330006 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine A (culture of all tips)
Number of subjects: 640
Study 21330006 — intervention group
Group type: COMPARATOR
Intervention: Routine B (culture only of tips from patients with concomitant bacteraemia or fungaemia)
Number of subjects: 640
Study 19377384 — intervention group
Group type: COMPARATOR
Intervention: DES
Number of subjects: 375
Study 19377384 — intervention group
Group type: COMPARATOR
Intervention: Prednisone treatment (40-day after BMS implantation)
Number of subjects: 375
Study 19377384 — intervention group
Group type: COMPARATOR
Intervention: BMS
Number of subjects: 375
Study 17098084 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day rimonabant
Number of subjects: 1047
Study 17098084 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day rimonabant
Number of subjects: 1047
Study 17098084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1047
Study 15446643 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental backpack
Number of subjects: 19
Study 15446643 — intervention group
Group type: COMPARATOR
Intervention: Personal traditional backpacks
Number of subjects: 19
Study 11760591 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intra-uterine system (levonorgestrel IUS; Mirena)
Number of subjects: 0
Study 9521264 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate withdrawal of AEDs (n = 78)
Number of subjects: 161
Study 9521264 — intervention group
Group type: COMPARATOR
Intervention: Continuation of treatment for another 6 months followed by withdrawal (n = 83)
Number of subjects: 161
Study 9521264 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 161
Study 7868437 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (1,000 IU/day)
Number of subjects: 7
Study 7868437 — intervention group
Group type: COMPARATOR
Intervention: Control (before vitamin E supplementation)
Number of subjects: 7
Study 7868437 — intervention group
Group type: COMPARATOR
Intervention: Control (after vitamin E supplementation)
Number of subjects: 7
Study 2807448 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy (ORT) introduced by health workers
Number of subjects: 200
Study 2807448 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy (ORT) introduced by health volunteers
Number of subjects: 200
Study 2807448 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy (ORT)
Number of subjects: 200
Study 2807448 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ORT)
Number of subjects: 200
Study 781965 — intervention group
Group type: EXPERIMENTAL
Intervention: PAS plus isoniazid daily
Number of subjects: 0
Study 781965 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptomycin plus isoniazid twice a week
Number of subjects: 0
Study 781965 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptomycin plus isoniazid twice a week for 1 year, then once a week
Number of subjects: 0
Study 30609164 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone treatment for 5 days
Number of subjects: 25
Study 30609164 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 5 days
Number of subjects: 25
Study 28268064 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg orally twice per day plus trametinib 2 mg orally once per day
Number of subjects: 25
Study 25097102 — intervention group
Group type: EXPERIMENTAL
Intervention: CG100649 (8-mg loading dose + 2 mg/d, 10-mg loading dose + 4 mg/d, or 12-mg loading dose + 8 mg/d)
Number of subjects: 16
Study 25097102 — intervention group
Group type: EXPERIMENTAL
Intervention: CG100649 (12-mg loading dose + 8 mg/d)
Number of subjects: 16
Study 25097102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 23756962 — intervention group
Group type: EXPERIMENTAL
Intervention: Toltrazuril 5 % suspension (Baycox®, Bayer)
Number of subjects: 170
Study 23756962 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclazuril (Vecoxan®, Janssen‐Cilag)
Number of subjects: 170
Study 23756962 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group (C)
Number of subjects: 170
Study 23193862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cast post and core (base metal, Ni‐Cr)
Number of subjects: 100
Study 23193862 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass‐fiber post and composite resin core
Number of subjects: 100
Study 23193862 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon fiber post with composite resin core
Number of subjects: 100
Study 23193862 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated parallel‐sided titanium post and composite resin core
Number of subjects: 100
Study 19890745 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 5 microg/kg (n = 17)
Number of subjects: 42
Study 19890745 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 2.5 mg/ml (n = 12)
Number of subjects: 42
Study 19890745 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control group, n = 13)
Number of subjects: 42
Study 16502766 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (250 mg) + Fexofenadine (60 mg)
Number of subjects: 6
Study 16502766 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine (60 mg) alone
Number of subjects: 6
Study 12770969 — intervention group
Group type: EXPERIMENTAL
Intervention: PACG
Number of subjects: 74
Study 12770969 — intervention group
Group type: EXPERIMENTAL
Intervention: POAG
Number of subjects: 74
Study 12770969 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 74
Study 10866423 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile normothermic cardiopulmonary bypass (CPB)
Number of subjects: 28
Study 10866423 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile normothermic cardiopulmonary bypass (CPB)
Number of subjects: 28
Study 10866423 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile normothermic CPB
Number of subjects: 28
Study 8862223 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary albumin excretion (UAE)
Number of subjects: 120
Study 8862223 — intervention group
Group type: EXPERIMENTAL
Intervention: UAE
Number of subjects: 120
Study 2033028 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright (2500 lux) full-spectrum fluorescent light with UV
Number of subjects: 11
Study 2033028 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright (2500 lux) full-spectrum fluorescent light without UV
Number of subjects: 11
Study 2033028 — intervention group
Group type: COMPARATOR
Intervention: Dim (500 lux) light control
Number of subjects: 11
Study 7013056 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole 100 mg
Number of subjects: 40
Study 7013056 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 40
Study 31265163 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg orally once daily until disease progression
Number of subjects: 81
Study 27628617 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted lumbar puncture (UALP)
Number of subjects: 43
Study 27628617 — intervention group
Group type: COMPARATOR
Intervention: Standard lumbar puncture (SLP)
Number of subjects: 43
Study 26095435 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week group-based lifestyle intervention
Number of subjects: 32
Study 22169619 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified gay-specific cognitive behavioral therapy combined with low-cost contingency management (GCBT+CM)
Number of subjects: 0
Study 22169619 — intervention group
Group type: COMPARATOR
Intervention: Original gay-specific cognitive behavioral therapy (GCBT)
Number of subjects: 0
Study 22796581 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg) administered preoperatively and postoperatively
Number of subjects: 151
Study 22796581 — intervention group
Group type: COMPARATOR
Intervention: Control group (no statin therapy)
Number of subjects: 151
Study 20840480 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus BID (Prograf)
Number of subjects: 667
Study 20840480 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus QD (Advagraf)
Number of subjects: 667
Study 20840480 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Tacrolimus QD and BID
Number of subjects: 667
Study 16949710 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of live attenuated hepatitis A vaccine
Number of subjects: 134
Study 16949710 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of live attenuated hepatitis A vaccine
Number of subjects: 134
Study 15590232 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making approach to PSA screening
Number of subjects: 0
Study 15590232 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual decision-making by patients
Number of subjects: 0
Study 12149467 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 treatment
Number of subjects: 6
Study 10064632 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg orally once daily)
Number of subjects: 535
Study 10064632 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate (500/125 mg orally 3 times daily)
Number of subjects: 535
Study 10064632 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 535
Study 10064632 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate
Number of subjects: 535
Study 7497157 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at hospital
Number of subjects: 499
Study 7497157 — intervention group
Group type: COMPARATOR
Intervention: Attendance at GP surgeries
Number of subjects: 499
Study 3056477 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing
Number of subjects: 16
Study 3056477 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 16
Study 3056477 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DDD and VVI pacing
Number of subjects: 16
Study 31882508 — intervention group
Group type: EXPERIMENTAL
Intervention: StrataXRT® (film-forming silicone gel)
Number of subjects: 56
Study 31882508 — intervention group
Group type: COMPARATOR
Intervention: X‐derm® (moisturizing cream)
Number of subjects: 56
Study 30945097 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic subtotal esophagectomy with bilateral cervical lymphadenectomy
Number of subjects: 42
Study 28430117 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 118
Study 25545400 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin XL
Number of subjects: 64
Study 25545400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 23276318 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Diary Composite (DDC)
Number of subjects: 89
Study 23276318 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Self-Report (GSR)
Number of subjects: 89
Study 21617330 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 40 mg
Number of subjects: 984
Study 21617330 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 984
Study 18298204 — intervention group
Group type: EXPERIMENTAL
Intervention: LED lamp (10 seconds curing time)
Number of subjects: 30
Study 18298204 — intervention group
Group type: COMPARATOR
Intervention: Halogen lamp (20 seconds curing time)
Number of subjects: 30
Study 20946173 — intervention group
Group type: EXPERIMENTAL
Intervention: GSNO gel (100 µM)
Number of subjects: 40
Study 20946173 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 40
Study 15921511 — intervention group
Group type: EXPERIMENTAL
Intervention: PncOMPC vaccine
Number of subjects: 111
Study 15921511 — intervention group
Group type: EXPERIMENTAL
Intervention: PncPS booster
Number of subjects: 111
Study 15921511 — intervention group
Group type: COMPARATOR
Intervention: Control group (Hepatitis B vaccine)
Number of subjects: 111
Study 11799385 — intervention group
Group type: EXPERIMENTAL
Intervention: EpiPen Jr (0.15 mg)
Number of subjects: 0
Study 11799385 — intervention group
Group type: COMPARATOR
Intervention: EpiPen (0.3 mg)
Number of subjects: 0
Study 10182195 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 662
Study 10182195 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 662
Study 10182195 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin
Number of subjects: 662
Study 10182195 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin
Number of subjects: 662
Study 7975870 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethylrutosides (HR) at a dose of 1000 mg/day for at least 4 weeks
Number of subjects: 1973
Study 7975870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1973
Study 3178373 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg of triazolam
Number of subjects: 10
Study 3178373 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg of triazolam
Number of subjects: 10
Study 3178373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11568587 — intervention group
Group type: EXPERIMENTAL
Intervention: Inlay tympanoplasty
Number of subjects: 70
Study 11568587 — intervention group
Group type: COMPARATOR
Intervention: Underlay tympanoplasty
Number of subjects: 70
Study 30791961 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip intervention
Number of subjects: 40
Study 30279086 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.20 mm uniplanar clear corneal incisions
Number of subjects: 100
Study 30279086 — intervention group
Group type: COMPARATOR
Intervention: 2.85 mm uniplanar clear corneal incisions
Number of subjects: 100
Study 26733083 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Physical Activity (EPA) group with individualized exercise programming including personalized step goals and resistance band training
Number of subjects: 39
Study 26733083 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC) group with general activity goal
Number of subjects: 39
Study 24865869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 188
Study 24865869 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Therapy (BT)
Number of subjects: 188
Study 24865869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 188
Study 22336590 — intervention group
Group type: EXPERIMENTAL
Intervention: diet (‐600 kcal) alone
Number of subjects: 60